Baxter Recalls WatchCare Incontinence Management System, Due To Interference Risk

  • The FDA classified Baxter International Inc's BAX recall of hospital bed systems as the most serious type of concern that it could lead to life-threatening injuries or death.
  • Baxter initiated the recall of its WatchCare Incontinence Management System, which is used to discreetly alert an incontinent patient's caregiver of an incontinence event.
  • Baxter warned users about the potential for WatchCare's radio frequencies to interfere with other medical devices.
  • The device was found to interfere with other nearby critical devices such as infusion pumps, insulin pumps, blood glucose sensors, and bladder scanners.
  • Related: Baxter Q3 Performance underwhelms Investors, FY22 Guidance Lags Consensus.
  • The FDA said the interference from WatchCare may lead to erroneous readings or malfunctions on other devices, causing inappropriate medical treatment for patients.
  • Baxter recalled 8,550 WatchCare devices distributed between August 1, 2018, and September 1, 2022.
  • The FDA said the recall was based on 96 reported complaints of interference with no reports of injuries or death related to the product.
  • Baxter said it has sought location and removal of the device from clinical care areas, where possible.
  • Many of the recalled WatchCare devices were manufactured by Hillrom, which Baxter acquired in late 2021.
  • Price Action: BAX shares closed at $56.30 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: Large CapNewsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!